Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Jan 13, 2023 1:04pm

150 Views

Post# 35221575

Diagnostic company Illumina thumbs nose at EU Commission

Illumina's takeover of Grail is moving ahead even at the expense of the EU Commission anti-competitive ruling.

“We disagree that the Commission has jurisdiction to review the merger, and with the premise of the interim measures itself and with a number of its provisions, the Commission has exceeded its authority,” it said.

https://www.reuters.com/news/archive/businessNews/article/grail-m-a-illumina-eu/illumina-challenges-eu-order-to-keep-grail-separate-idUSKBN2TP0VU

<< Previous

Bullboard Posts

Next >>

Desert Gold Ventures - A jewel for the investor?